toxylact: A02ag andiacids & spasmolytics
The first professional lActological database in the word
Antacids with antispasmodics (ATC A02AG) pose a lactation risk profile largely driven by the anticholinergic antispasmodic component, which can be incompatible with breastfeeding in many cases and requires strict individual assessment.
Pharmacological overview
A02AG includes fixed‑dose combinations where the primary therapeutic intent is antacid effect, with an added antispasmodic to manage upper dyspepsia with flatulence and visceral abdominal colic. Antacid components are typically local-acting gastric buffers with low systemic absorption, while antispasmodics are systemically active anticholinergics targeting muscarinic receptors in the gastrointestinal tract.
From a clinical perspective, the rationale for combining an antacid with an antispasmodic is the frequent coexistence of epigastric burning, bloating, and colicky visceral pain in functional and acid‑related upper gastrointestinal disorders. Although A02AG is recognized in the WHO ATC system, there are currently no registered products of this class in Bulgaria.
Toxicological profile
The toxicological assessment of A02AG products is dominated by the profile of the most toxic component in the combination, which in practice is usually the antispasmodic. Classical anticholinergic spasmolytics such as atropine, butylscopolamine, and methanthelinium share a muscarinic blocking effect that can provoke a spectrum of dose‑dependent adverse reactions in adults and neonates.
Atropine is a belladonna alkaloid and prototypical parasympatholytic that produces a complete muscarinic receptor blockade; after maternal administration, it achieves a milk:plasma ratio around 1:1, so breast milk concentrations closely mirror maternal plasma levels. Atropine intoxication is characterized by flushing, tachycardia, marked nervous hyperexcitability, and transient amaurosis, and similar toxicity is expected with its synthetic analogues that share the same anticholinergic mechanism.
Butylscopolamine is a widely used antispasmodic with relatively poor oral bioavailability, yet it retains an atropine‑like anticholinergic effect and is considered contraindicated during lactation because of the potential for serious neonatal toxicity. Methanthelinium, used for hyperhidrosis, irritable bowel syndrome, and gastrointestinal cramps, has an anticholinergic effect comparable to atropine and therefore shares the same conceptual risk in breastfeeding mothers.
Lactation risk and mechanisms
For breastfed neonates and young infants, the principal toxicodynamic concern is anticholinergic cardiotoxicity, ranging from sinus tachycardia in mild exposure to torsade‑like ventricular tachycardia and even sudden cardiac death in severe cases. Because many antispasmodics can reach breast milk in concentrations similar to maternal plasma, and the neonatal myocardium and autonomic nervous system are particularly vulnerable, combinations in A02AG carry a potentially high lactation risk driven by the spasmolytic component.
The local antacid ingredients per se have low systemic absorption and, in most standard references, are not considered significant lactation hazards when used alone in usual doses. However, in fixed‑dose products these relatively safe antacids cannot mitigate the systemic anticholinergic toxicity of the concomitant spasmolytic, so the overall risk category must follow the most hazardous ingredient.
Toxicolactological categorization
Using the four‑level toxicological lactation schema, the lactation category for A02AG products must be assigned according to the highest‑risk component in the combination. If the antispasmodic generates milk concentrations similar to or higher than plasma and has a strong toxic profile for the neonate, the product falls into toxicological lactation category IV, meaning an incompatibility with breastfeeding and the need to either stop lactation or choose a lower‑risk alternative.
Category III applies when the drug and/or its metabolites achieve milk concentrations equal to or higher than plasma, and clinically relevant neonatal toxicity is plausible, requiring temporary interruption of breastfeeding for the full elimination period of the drug. Categories I and II, which correspond to negligible or clinically insignificant exposure via milk, are generally reserved for agents that either do not reach breast milk or do so in amounts insufficient to cause harm, and these categories rarely apply to potent systemic anticholinergics used as spasmolytics.
Clinical guidance in breastfeeding
In routine practice there are no ready‑made universal algorithms for A02AG during lactation; a case‑by‑case evaluation is needed, supported by detailed knowledge of the individual monographs of each component. When an antispasmodic is genuinely required in a breastfeeding woman, preference should be given to agents with the lowest anticholinergic potential and better characterized lactation safety, such as oxybutynin, which is mainly indicated for urinary incontinence rather than dyspepsia, or parenteral butylscopolamine as a lower‑toxicity option under controlled conditions.
Maternal diarrhea should not be treated routinely with anticholinergics during breastfeeding, because increased intestinal permeability can enhance oral absorption and bioavailability of these compounds, thereby increasing neonatal exposure and toxicity risk via breast milk. General lactation‑medicine principles also apply: if exposure to a highly toxic anticholinergic is unavoidable, breastfeeding should be interrupted for the duration of treatment and the subsequent washout period, with milk expression and discarding used to maintain lactation until a safer regimen is possible.



